Lynn Seely - 14 Mar 2025 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role: President and CEO, Director
Signature: /s/ Matthew Lang, as Attorney-in-Fact
Issuer symbol: LYEL
Transactions as of: 14 Mar 2025
Net transactions value: +$106,190
Form type: 4
Filing time: 18 Mar 2025, 18:59:18 UTC
Previous filing: 26 Feb 2025
Next filing: 24 Jun 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LYEL	Common Stock	Purchase	$106,190	+175,000	+33%	$0.6068	712,500	14 Mar 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported above reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $0.59980 to $0.62020, inclusive. Upon request from the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this range.

Content

The price reported above reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $0.59980 to $0.62020, inclusive. Upon request from the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this range.